NCT03122717 2025-11-12
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
11 trialsNCT06071013 2025-01-23
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
Phase 1/2 Recruiting
NCT01513174 2024-06-28
GOAL
Spanish Lung Cancer Group
Phase 1/2 Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT00062270 2015-10-08
Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT01039948 2015-04-08
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00809237 2013-12-10
Hydroxychloroquine and Gefitinib to Treat Lung Cancer
National University Hospital, Singapore
Phase 1/2 Unknown
NCT00268255 2013-04-16
Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Withdrawn
NCT00098462 2012-10-04
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn
NCT00238628 2010-07-20
A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer
Stanford University
Phase 1/2 Completed